Address: Sadovaya Plaza, 12th Floor, 7 Dolgorukovskaya Street, Moscow 127006,Russia
Tel: + 7 495 787 2700
Web: http://www.bakermckenzie.com/Russia/
Baker & McKenzie was the first international law firm to open an office in Moscow in 1989. Since then we have built a reputation as an experienced and reliable legal adviser, combining deep knowledge of local law with seamless execution across borders and practices.
We are one of the largest and strongest legal teams in Russia, and our antitrust, dispute resolution, employment, mergers and acquisitions, tax, real estate, and intellectual property practices are consistently ranked among the country’s leading. Our offices in Moscow and St. Petersburg have more than 120 qualified lawyers combined, including nearly 30 partners providing sophisticated legal advice to leading Russian and international corporations, banks and financial institutions.
Since opening our Moscow office in 1989, the research based pharmaceuticals industry has looked to us for legal support and advice in Russia and across the CIS. We have assisted in the foundation of the Association of International Pharmaceutical Manufacturers (AIPM) and served as its legal advisers for 15 years. We have also acted as outside counsel to the Healthcare Committee of the European Business Association of Ukraine, and to the association of multinational research based pharmaceutical manufacturers PRADA in Ukraine.
We received an award from the Association of International Pharmaceutical Manufacturers 2009 for our Outstanding Contribution to the Development of the Legal Organized Open Market for Pharmaceuticals in Russia.
We can advise research based multinational pharmaceutical companies on a wide range of issues associated with their operations throughout the CIS, including:
• Registration and circulation of medicines, medical equipment and products;
• Advertising and marketing regulations;
• Commercial agreements, including distribution and joint marketing agreements;
• Import and export requirements;
• Product liability;
• Regulation of clinical trials;
• Intellectual property, patent and trademark infringement (we were the first law firm to advise on a successful pharmaceutical patent infringement action before the Russian courts);
• Tax-effective structures for the import of medicines, medical equipment and products, maintenance of consignment stock and distribution mechanisms to take maximum advantage of the customs and tax benefits available to the pharmaceutical industry;
• Representation and defense of clients’ interests before tax and customs authorities in pre-trial proceedings, as well as in courts;
• Tolling arrangements and the adaptation of standard agreements in this connection, for use in Russia; and
• Recovery of receivables from Russian distributors by way of litigation and insolvency proceedings.
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
